Bioavailability of Iron Formulations
Oral ferrous iron salts (ferrous sulfate, ferrous gluconate, ferrous fumarate) have substantially superior bioavailability compared to ferric (trivalent) iron preparations, with ferrous iron absorbed up to 16 times better than ferric iron 1. Among oral formulations, no single ferrous salt demonstrates superiority over another, making ferrous sulfate the preferred choice due to lowest cost 2.
Oral Iron Bioavailability
Ferrous vs. Ferric Iron
- Ferrous (Fe2+) iron preparations: Bioavailability ranges from 46-100% in quick-release formulations 1
- Ferric (Fe3+) iron preparations: Dramatically inferior bioavailability of only 6-29%, making them unsuitable for clinical use 1, 3
- Slow or sustained-release ferrous formulations show intermediate bioavailability of 31-47% 1
Optimizing Oral Iron Absorption
The bioavailability of oral ferrous iron can be enhanced through specific dosing strategies:
- Timing: Morning administration on an empty stomach maximizes absorption 4
- Vitamin C co-administration: Adding 80-100 mg ascorbic acid or citrus juice significantly improves absorption by forming iron chelates and reducing ferric to ferrous iron 2, 4
- Frequency: Once-daily or alternate-day dosing is optimal, as hepcidin elevation blocks further absorption for up to 48 hours after each dose 2
Critical absorption inhibitors to avoid: Tea, coffee, milk, calcium supplements, antacids, H2 blockers, proton pump inhibitors, and food (especially cereals/grains) markedly reduce bioavailability 2, 4.
Alternative Oral Formulations
Newer products like iron protein succinylate, liposomal iron, and sucrosomial iron may offer better gastrointestinal tolerance with similar efficacy, though they are substantially more expensive and pediatric data remain limited 5, 6. Carbonyl iron shows excellent bioavailability with an important safety advantage in accidental overdose scenarios 6.
Intravenous Iron Bioavailability
All modern IV iron formulations achieve near-complete bioavailability (approaching 100%) as they bypass intestinal absorption entirely 7, 2. The key differences lie not in bioavailability but in pharmacokinetics, safety profiles, and time-dependent effects.
Comparative Performance by Timeframe
Recent network meta-analysis reveals important temporal trade-offs 8:
4-8 weeks (rapid repletion phase):
- Ferric carboxymaltose: Most consistent increases in iron stores (ferritin/transferrin saturation) but highest risk of hypophosphatemia
- Hemoglobin responses broadly comparable between ferric carboxymaltose and ferric derisomaltose
12-24 weeks (maintenance phase):
- Differences in iron stores attenuate across formulations
- Ferric derisomaltose and iron sucrose: Generally favored when mineral safety is prioritized (e.g., chronic kidney disease, inflammatory bowel disease) 8
Formulation-Specific Considerations
All non-dextran IV formulations (ferric carboxymaltose, ferric derisomaltose, iron sucrose, ferumoxytol, iron isomaltoside) share equal or near-equal efficacy and safety profiles 9. Single-dose or two-dose regimens (750-1000 mg per infusion) are strongly preferred over multiple-dose protocols 2.
Safety Profile
- True anaphylaxis: Exceedingly rare at <1:200,000 administrations 7, 2
- Complement activation-related pseudo-allergy (CARPA): Occurs in approximately 1:200 administrations, physiologically distinct from anaphylaxis 7, 2
- Mild reactions managed by pausing and restarting infusion at slower rate; diphenhydramine should be avoided as side effects can mimic worsening reactions 2
Clinical Decision Algorithm
Choose ferric carboxymaltose when:
- Rapid iron repletion is critical (4-8 week timeframe)
- Monitoring for hypophosphatemia is feasible
- Patient can tolerate 1-2 infusion visits
Choose ferric derisomaltose or iron sucrose when:
- Safety predominates (chronic kidney disease, inflammatory bowel disease)
- Longer-term maintenance therapy planned
- Hypophosphatemia risk must be minimized
Choose oral ferrous sulfate when:
- Patient can tolerate gastrointestinal side effects (constipation 12%, diarrhea 8%, nausea 11%) 2
- Cost is primary consideration
- Adequate absorption expected (no malabsorption, active inflammation, or ongoing blood loss exceeding oral replacement capacity)
Common Pitfall
Real-world data demonstrates oral ferrous sulfate frequently fails to achieve adequate iron store repletion (ferritin ≥30 µg/L), with post-treatment ferritin remaining at 8.68±4.38 µg/L at 3 months versus 412.60±95.87 µg/L with IV ferric carboxymaltose 10. Do not persist with oral iron if ferritin fails to increase within one month or hemoglobin fails to increase by 1 g/dL within two weeks 2.